ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Paris, Île-de-France, FRA:

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Paris Cedex 5, France and 125 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 213 other locations

(PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian ....

Active, not recruiting
Fallopian Tube Cancer
Ovarian Cancer
Drug: Niraparib
Drug: ZN-c3

Phase 1, Phase 2

K-Group Beta

Villejuif, France and 19 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Paris, France and 46 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 176 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Paris, France and 102 other locations

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Paris, France and 53 other locations

chemotherapy and in maintenance, in patients presenting epithelial ovarian cancer (including patients with primary peritoneal and /...

Active, not recruiting
Ovarian Cancer
Drug: placebo + avastin + platinum-based chemotherapy
Drug: atezolizumab + avastin + platinum-based chemotherapy

Phase 3

ARCAGY/ GINECO GROUP

Paris, France and 74 other locations

Recently updated

to explore the safety and feasibility in neo-adjuvant first-line ovarian cancer (including patients with primary peritoneal or fall...

Active, not recruiting
Ovarian Cancer
Drug: ARM A Durvalumab/chemotherapy association
Drug: ARM B Durvalumab/Tremelimumab/chemotherapy association

Phase 1, Phase 2

ARCAGY/ GINECO GROUP

Paris, France and 10 other locations

The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian...

Enrolling
Low Grade Serous Ovarian Carcinoma
Adult Type Granulosa Cell Tumor
Drug: Abemaciclib
Drug: Letrozole

Phase 2

Universitaire Ziekenhuizen KU Leuven

Paris, Île-de-France, France and 11 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems